Top

Reviews in Endocrine and Metabolic Disorders

Published in:

Open Access 10-05-2023 | Obesity

Towards an adiposity-related disease framework for the diagnosis and management of obesities

Authors: Carolina M. Perdomo, Icíar Avilés-Olmos, Dror Dicker, Gema Frühbeck

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 5/2023

Abstract

Obesity is a complex disease that relapses frequently and associates with multiple complications that comprise a worldwide health priority because of its rising prevalence and association with numerous complications, including metabolic disorders, mechanic pathologies, and cancer, among others. Noteworthy, excess adiposity is accompanied by chronic inflammation, oxidative stress, insulin resistance, and subsequent organ dysfunction. This dysfunctional adipose tissue is initially stored in the visceral depot, overflowing subsequently to produce lipotoxicity in ectopic depots like liver, heart, muscle, and pancreas, among others. People living with obesity need a diagnostic approach that considers an exhaustive pathophysiology and complications assessment. Thus, it is essential to warrant a holistic diagnosis and management that guarantees an adequate health status, and quality of life. The present review summarizes the different complications associated with obesity, at the same time, we aim to fostering a novel framework that enhances a patient-centered approach to obesity management in the precision medicine era.

Frühbeck G, Busetto L, Dicker D, et al. The ABCD of obesity: An EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts. 2019;12:131–6. https://doi.org/10.1159/000497124.CrossRefPubMedPubMedCentral

Bhaskaran K, dos-Santos-Silva I, Leon DA, et al. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6:944–53. https://doi.org/10.1016/S2213-8587(18)30288-2.CrossRefPubMedPubMedCentral

Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;4(353):i2156. https://doi.org/10.1136/bmj.i2156.CrossRef

Pincu Y, Yoel U, Haim Y, et al. Assessing obesity-related adipose tissue disease (OrAD) to improve precision medicine for patients living with obesity. Front Endocrinol (Lausanne). 2022;13:1–17. https://doi.org/10.3389/fendo.2022.860799.CrossRef

Hamjane N, Benyahya F, Nourouti NG, et al. Cardiovascular diseases and metabolic abnormalities associated with obesity: What is the role of inflammatory responses? A systematic review. Microvasc Res. 2020;131. https://doi.org/10.1016/j.mvr.2020.104023.

Cypess AM. Reassessing Human Adipose Tissue. N Engl J Med. 2022;386:768–79. https://doi.org/10.1056/nejmra2032804.CrossRefPubMed

Sakers A, De Siqueira MK, Seale P, Villanueva CJ. Adipose-tissue plasticity in health and disease. Cell. 2022;185:419–46. https://doi.org/10.1016/j.cell.2021.12.016.CrossRefPubMed

Rodríguez A, Ezquerro S, Méndez-Giménez L, et al. Revisiting the adipocyte: A model for integration of cytokine signaling in the regulation of energy metabolism. Am J Physiol - Endocrinol Metab. 2015;309:E691–714. https://doi.org/10.1152/ajpendo.00297.2015.CrossRefPubMed

Liang W, Qi Y, Yi H, et al. The roles of adipose tissue macrophages in human disease. Front Immunol. 2022;13:1–11. https://doi.org/10.3389/fimmu.2022.908749.

10.

Moreno-Navarrete JM, Escoté X, Ortega F, et al. A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. Diabetologia. 2013;56:2524–37. https://doi.org/10.1007/s00125-013-3015-9.CrossRefPubMed

11.

Unamuno X, Gómez-Ambrosi J, Rodríguez A, et al. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48:1–11. https://doi.org/10.1111/eci.12997.CrossRef

12.

Lipke K, Kubis-Kubiak A, Piwowar A. Molecular mechanism of lipotoxicity as an interesting aspect in the development of pathological states—current view of knowledge. Cells. 2022;11. https://doi.org/10.3390/cells11050844.

13.

De Fano M, Bartolini D, Tortoioli C, et al. Adipose tissue plasticity in response to pathophysiological cues: A connecting link between obesity and its associated comorbidities. Int J Mol Sci. 2022;23. https://doi.org/10.3390/ijms23105511.

14.

Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxidants Redox Signal. 2013;19:1110–1120. https://doi.org/10.1089/ars.2012.4641.

15.

Perdomo CM, Frühbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients. 2019;11:1–25. https://doi.org/10.3390/nu11030677.CrossRef

16.

Ferreira FG, Reitz LK, Valmorbida A, et al. Metabolically unhealthy and overweight phenotypes are associated with increased levels of inflammatory cytokines: a population-based study. Nutrition. 2022;96:111590. https://doi.org/10.1016/j.nut.2022.111590.

17.

Frühbeck G, Kiortsis DN, Catalán V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol. 2018;6:164–6. https://doi.org/10.1016/S2213-8587(17)30312-1.CrossRefPubMed

18.

Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease a scientific statement from the American Heart Association. Circulation. 2021;143:E984–1010. https://doi.org/10.1161/CIR.0000000000000973.CrossRefPubMedPubMedCentral

19.

Eckel N, Li Y, Kuxhaus O, et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6:714–24. https://doi.org/10.1016/S2213-8587(18)30137-2.CrossRefPubMed

20.

Yusuf S, Hawken S, Ounpuu S. INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–9. https://doi.org/10.1016/S0140-6736(05)67663-5.CrossRefPubMed

21.

Strazzullo P, D’Elia L, Cairella G, et al. Excess body weight and incidence of stroke: Meta-analysis of prospective studies with 2 million participants. Stroke. 2010;41:418–26. https://doi.org/10.1161/STROKEAHA.109.576967.CrossRef

22.

Horn JW, Feng T, Morkedal B, et al. Obesity and risk for first ischemic stroke depends on metabolic syndrome: The HUNT study. Stroke. 2021;52:3555–61. https://doi.org/10.1161/STROKEAHA.120.033016.CrossRefPubMed

23.

Katta N, Loethen T, Lavie CJ, Alpert MA. Obesity and coronary heart disease: Epidemiology, pathology, and coronary artery imaging. Curr Probl Cardiol. 2021;46:11–20. https://doi.org/10.1016/j.cpcardiol.2020.100655.CrossRef

24.

Mafort TT, Rufino R, Costa CH, Lopes AJ. Obesity: Systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. Multidiscip Respir Med. 2016;11:1–11. https://doi.org/10.1186/s40248-016-0066-z.CrossRef

25.

Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: A meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007;175:661–6. https://doi.org/10.1164/rccm.200611-1717OC.CrossRefPubMedPubMedCentral

26.

Stein PD, Matta F, Goldman J. Obesity and pulmonary embolism: The mounting evidence of risk and the mortality paradox. Thromb Res. 2011;128:518–23. https://doi.org/10.1016/j.thromres.2011.10.019.CrossRefPubMed

27.

Bonsignore MR, Baiamonte P, Mazzuca E, et al. Obstructive sleep apnea and comorbidities: A dangerous liaison. Multidiscip Respir Med. 2019;14:1–12. https://doi.org/10.1186/s40248-019-0172-9.CrossRef

28.

Rinella ME. Nonalcoholic fatty liver disease a systematic review. J Am Med Assoc. 2015;313:2263–73. https://doi.org/10.1001/jama.2015.5370.CrossRef

29.

Abenavoli L, Milic N, Di Renzo L, et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22(31):7006–16. https://doi.org/10.3748/wjg.v22.i31.7006.CrossRefPubMedPubMedCentral

30.

Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22. https://doi.org/10.1038/s41591-018-0104-9.CrossRefPubMedPubMedCentral

31.

Budd J, Cusi K. Non-alcoholic fatty liver disease: What does the primary care physician need to know? Am J Med. 2020;133(5):536–43. https://doi.org/10.1016/j.amjmed.2020.01.007.CrossRefPubMed

32.

Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical setting. Endocr Pract. 2022;28:528–62. https://doi.org/10.1016/j.eprac.2022.03.010.CrossRefPubMed

33.

Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e10. https://doi.org/10.1053/j.gastro.2015.04.043.CrossRefPubMed

34.

Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: A systematic review and meta-analysis. Am J Gastroenterol. 2006;101:2619–28. https://doi.org/10.1111/j.1572-0241.2006.00849.x.CrossRefPubMed

35.

Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol. 2015;30:1009–19. https://doi.org/10.1007/s10654-015-0081-y.CrossRefPubMed

36.

Fraquelli M, Pagliarulo M, Colucci A, et al. Gallbladder motility in obesity, diabetes mellitus and coeliac disease. Dig Liver Dis. 2003;35:12–6. https://doi.org/10.1016/S1590-8658(03)00087-2.CrossRef

37.

Aune D, Mahamat-Saleh Y, Norat T, Riboli E. High body mass index and central adiposity is associated with increased risk of acute pancreatitis: a meta-analysis. Dig Dis Sci. 2021;66:1249–67. https://doi.org/10.1007/s10620-020-06275-6.CrossRefPubMed

38.

Poddar M, Chetty Y, Chetty VT. How does obesity affect the endocrine system? A narrative review. Clin Obes. 2017;7:136–44. https://doi.org/10.1111/cob.12184.CrossRefPubMed

39.

Taylor R. Calorie restriction for long-term remission of type 2 diabetes. Clin Med J R Coll Physicians London. 2019;19:37–42. https://doi.org/10.7861/clinmedicine.19-1-37.CrossRef

40.

Kaps L, Labenz C, Galle PR, Weinmann-menke J, Kostev K. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J. 2020;8(8):942–8. https://doi.org/10.1177/2050640620944098.CrossRef

41.

Tuero C, Valenti V, Rotellar F, et al. Revisiting the ghrelin changes following bariatric and metabolic surgery. Obes Surg. 2020;30:2763–80. https://doi.org/10.1007/s11695-020-04601-5.CrossRefPubMed

42.

Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. Nutrients. 2019;11:1–13. https://doi.org/10.3390/nu11020454.CrossRef

43.

Semins MJ, Shore AD, Makary MA, et al. The impact of obesity on urinary tract infection risk. Urology. 2012;79:266–9. https://doi.org/10.1016/j.urology.2011.09.040.CrossRefPubMed

44.

Lai HH, Helmuth ME, Smith AR. Relationship between central obesity, general obesity, overactive bladder syndrome and urinary incontinence among male and female patients seeking care for their lower urinary tract symptoms. Urology. 2019;123:34–43. https://doi.org/10.1016/j.urology.2018.09.012.CrossRefPubMed

45.

Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. J Urol. 2013;189:102–6. https://doi.org/10.1016/j.juro.2012.11.029.CrossRef

46.

Ahmed MH, Ahmed HT, Khalil AA. Renal stone disease and obesity: What is important for urologists and nephrologists? Ren Fail. 2012;34:1348–54. https://doi.org/10.3109/0886022X.2012.723777.CrossRefPubMed

47.

Sinha MK, Collazo-Clavell ML, Rule A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int. 2007;72:100–7. https://doi.org/10.1038/sj.ki.5002194.CrossRefPubMed

48.

Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8. https://doi.org/10.7326/0003-4819-144-1-200601030-00006.CrossRefPubMed

49.

Martin WP, Bauer J, Coleman J, et al. Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in a tertiary nephrology centre. Clin Obes. 2020;10:1–12. https://doi.org/10.1111/cob.12402.CrossRef

50.

García-Carro C, Vergara A, Bermejo S, et al. A nephrologist perspective on obesity: from kidney injury to clinical management. Front Med. 2021;8:655871. https://doi.org/10.3389/fmed.2021.655871.CrossRef

51.

Foster MC, Hwang SJ, Massaro JM, et al. Association of subcutaneous and visceral adiposity with albuminuria: The framingham heart study. Obesity. 2011;19:1284–9. https://doi.org/10.1038/oby.2010.308.CrossRefPubMed

52.

Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: Hidden consequences of the epidemic. Am J Nephrol. 2017;45:283–91. https://doi.org/10.1159/000458467.CrossRefPubMed

53.

Deng Y, Zhao Q, Gong R. Association between metabolic associated fatty liver disease and chronic kidney disease: A cross-sectional study from NHANES 2017–2018. Diabetes, Metab Syndr Obes Targets Ther. 2021;14:1751–61. https://doi.org/10.2147/DMSO.S292926.CrossRef

54.

Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci. 2020;21(2):494. https://doi.org/10.3390/ijms21020494.CrossRefPubMedPubMedCentral

55.

Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15:321–35. https://doi.org/10.1159/000521241.CrossRefPubMedPubMedCentral

56.

Walsh TP, Arnold JB, Evans AM, et al. The association between body fat and musculoskeletal pain: A systematic review and meta-analysis. BMC Musculoskelet Disord. 2018;19:1–13. https://doi.org/10.1186/s12891-018-2137-0.CrossRef

57.

Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: Evidence, hypotheses and horizons - a scoping review. Obes Rev. 2014;15:578–86. https://doi.org/10.1111/obr.12173.CrossRefPubMedPubMedCentral

58.

Lu B, Hiraki LT, Sparks JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: A prospective cohort study. Ann Rheum Dis. 2014;73:1914–22. https://doi.org/10.1136/annrheumdis-2014-205459.CrossRefPubMed

59.

DeMarco MAMA, Maynard JW, Huizinga MM, et al. Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res. 2011;63:1108–14. https://doi.org/10.1002/acr.20479.CrossRef

60.

Nielsen SM, Bartels EM, Henriksen M, et al. Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies. Ann Rheum Dis. 2017;76:1870–82. https://doi.org/10.1136/annrheumdis-2017-211472.CrossRefPubMed

61.

Deng Y-T, Li Y-Z, Huang S-Y, et al. Association of life course adiposity with risk of incident dementia: a prospective cohort study of 322,336 participants. Mol Psychiatry. 2022;27:3385–95. https://doi.org/10.1038/s41380-022-01604-9.CrossRefPubMed

62.

Favieri F, Forte G, Casagrande M. The Executive Functions in Overweight and Obesity: A Systematic Review of Neuropsychological Cross-Sectional and Longitudinal Studies. Front Psychol. 2019;10:2126. https://doi.org/10.3389/fpsyg.2019.02126.CrossRefPubMedPubMedCentral

63.

Herrmann MJ, Tesar A, Beier J, et al. Grey matter alterations in obesity: A meta-analysis of whole-brain studies. Obes Rev. 2019;20:464–71. https://doi.org/10.1111/obr.12799.CrossRefPubMed

64.

Miller AA, Spencer SJ. Obesity and neuroinflammation: A pathway to cognitive impairment. Brain Behav Immun. 2014;42:10–21. https://doi.org/10.1016/j.bbi.2014.04.001.CrossRefPubMed

65.

Li J-W, Zong Y, Cao X-P, et al. Microglial priming in Alzheimer’s disease. Ann Transl Med. 2018;6:176. https://doi.org/10.21037/atm.2018.04.22.CrossRefPubMedPubMedCentral

66.

Zhou J, Mao L, Xu P, Wang Y. Effects of epigallocatechin gallate (EGCG) on energy expenditure and microglia-mediated hypothalamic inflammation in mice fed a high-fat diet. Nutrients. 2018;10:1681. https://doi.org/10.3390/nu10111681.CrossRefPubMedPubMedCentral

67.

Salas-Venegas V, Flores-Torres RP, Rodríguez-Cortés YM, et al. The obese brain: Mechanisms of systemic and local inflammation, and interventions to reverse the cognitive deficit. Front Integr Neurosci. 2022;16:1–19. https://doi.org/10.3389/fnint.2022.798995.CrossRef

68.

Moretti R, Caruso P. Small vessel disease: Ancient description, novel biomarkers. Int J Mol Sci. 2022;23:3508. https://doi.org/10.3390/ijms23073508.CrossRefPubMedPubMedCentral

69.

Westgate CSJ, Israelsen IME, Jensen RH, Eftekhari S. Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension. J Headache Pain. 2021;22:123. https://doi.org/10.1186/s10194-021-01337-0.CrossRefPubMedPubMedCentral

70.

Peterlin BL, Rapoport AM, Kurth T. Migraine and obesity: Epidemiology, mechanisms, and implications. Headache J Head Face Pain. 2010;50:631–48. https://doi.org/10.1111/j.1526-4610.2009.01554.x.CrossRef

71.

Callaghan BC, Xia R, Reynolds E, et al. Association between metabolic syndrome components and polyneuropathy in an obese population. JAMA Neurol. 2016;73:1468. https://doi.org/10.1001/jamaneurol.2016.3745.CrossRefPubMedPubMedCentral

72.

Lambert E, Sari CI, Dawood T, et al. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension. 2010;56:351–8. https://doi.org/10.1161/HYPERTENSIONAHA.110.155663.CrossRefPubMed

73.

Sarwer DB, Polonsky HM. The psychosocial burden of obesity. Endocrinol Metab Clin North Am. 2016;45:677–88. https://doi.org/10.1016/j.ecl.2016.04.016.CrossRefPubMedPubMedCentral

74.

Rubino F, Logue J, Bøgelund M, et al. Attitudes about the treatment of obesity among healthcare providers involved in the care of obesity-related diseases: A survey across medical specialties in multiple European countries. Obes Sci Pract. 2021;7:659–68. https://doi.org/10.1002/osp4.518.CrossRefPubMedPubMedCentral

75.

Wu YK, Berry DC. Impact of weight stigma on physiological and psychological health outcomes for overweight and obese adults: A systematic review. J Adv Nurs. 2018;74:1030–42. https://doi.org/10.1111/jan.13511.CrossRefPubMed

76.

Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26:485–97. https://doi.org/10.1038/s41591-020-0803-x.CrossRefPubMedPubMedCentral

77.

Weinberger NA, Kersting A, Riedel-Heller SG, Luck-Sikorski C. Body dissatisfaction in individuals with obesity compared to normal-weight individuals: A systematic review and meta-analysis. Obes Facts. 2017;9:424–41. https://doi.org/10.1159/000454837.CrossRef

78.

Perry C, Guillory TS, Dilks SS. Obesity and psychiatric disorders. Nurs Clin North Am. 2021;56(4):553–63. https://doi.org/10.1016/j.cnur.2021.07.010.CrossRefPubMed

79.

WHO European Regional Obesity Report 2022. Copenhagen: WHO Regional Office for Europe. 2022. Licence: CC BY-NC-SA 3.0 IGO.

80.

Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35. https://doi.org/10.1016/j.metabol.2018.11.001.CrossRefPubMed

81.

Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Adipose tissue immunity and cancer. Front Physiol. 2013;1–13. https://doi.org/10.3389/fphys.2013.00275.

82.

Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, et al. Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne). 2014;5:1–17. https://doi.org/10.3389/fendo.2014.00065.CrossRef

83.

Yárnoz-Esquiroz P, Olazarán L, Aguas-Ayesa M, et al. ‘Obesities’: Position statement on a complex disease entity with multifaceted drivers. Eur J Clin Invest. 2022;52. https://doi.org/10.1111/eci.13811.

84.

Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res 2020:1477–1500. https://doi.org/10.1161/CIRCRESAHA.120.316101.

85.

Neeland IJ, Poirier P, Després J-P. Cardiovascular and metabolic heterogeneity of obesity. Circulation. 2018;137:1391–406. https://doi.org/10.1161/circulationaha.117.029617.CrossRefPubMedPubMedCentral

86.

Cameron AJ, Magliano DJ, Söderberg S. A systematic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality. Obes Rev. 2013;14:86–94. https://doi.org/10.1111/j.1467-789X.2012.01051.x.CrossRefPubMed

87.

Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat Rev Endocrinol. 2020;16:177–89. https://doi.org/10.1038/s41574-019-0310-7.CrossRefPubMedPubMedCentral

88.

Diemer FS, Brewster LM, Haan YC, Oehlers GP, van Montfrans GA, Nahar-van Venrooij LMW. Body composition measures and cardiovascular risk in high-risk ethnic groups. Clin Nutr. 2019;38:450–6. https://doi.org/10.1016/j.clnu.2017.11.012.CrossRefPubMed

89.

Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: Systematic review and meta-analysis. Obes Rev. 2012;13:275–86. https://doi.org/10.1111/j.1467-789X.2011.00952.x.CrossRefPubMed

90.

Gibson S, Ashwell M. A simple cut-off for waist-to-height ratio (0·5) can act as an indicator for cardiometabolic risk: Recent data from adults in the Health Survey for England. Br J Nutr. 2020;123:681–90. https://doi.org/10.1017/S0007114519003301.CrossRefPubMed

91.

Chen N, Hu LK, Sun Y, et al. Associations of waist-to-height ratio with the incidence of type 2 diabetes and mediation analysis: Two independent cohort studies. Obes Res Clin Pract. 2023:1–7. https://doi.org/10.1016/j.orcp.2022.12.005.

92.

Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:1–41. https://doi.org/10.3389/fcvm.2020.00022.CrossRef

93.

Kaess BM, Pedley A, Massaro JM, et al. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012;55:2622–30. https://doi.org/10.1007/s00125-012-2639-5.CrossRefPubMedPubMedCentral

94.

Aneni EC, Bittencourt MS, Teng C, et al. The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. Am J Prev Cardiol. 2020;4:100097. https://doi.org/10.1016/j.ajpc.2020.100097.CrossRefPubMedPubMedCentral

95.

Cosson E, Nguyen MT, Rezgani I, et al. Epicardial adipose tissue volume and myocardial ischemia in asymptomatic people living with diabetes: a cross-sectional study. Cardiovasc Diabetol. 2021;20:1–10. https://doi.org/10.1186/s12933-021-01420-5.CrossRef

96.

Sharma AM. M, M, M & M: A mnemonic for assessing obesity. Obes Rev. 2010;11:808–9. https://doi.org/10.1111/j.1467-789X.2010.00766.x.CrossRefPubMed

97.

Gómez-Ambrosi J, Salvador J, Páramo JA, et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem. 2002;35:315–20. https://doi.org/10.1016/S0009-9120(02)00320-X.CrossRefPubMed

98.

Frühbeck G, Catalán V, Rodríguez A, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7:1–8. https://doi.org/10.1038/s41598-017-06997-0.CrossRef

99.

Ghantous CM, Azrak Z, Hanache S, et al. Differential role of leptin and adiponectin in cardiovascular system. Int J Endocrinol. 2015;534320. https://doi.org/10.1155/2015/534320.

100.

Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7:57–62. https://doi.org/10.1080/21623945.2017.1402151.CrossRefPubMed

101.

Landecho MF, Tuero C, Valentí V, et al. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk. Nutrients. 2019;11:1–16. https://doi.org/10.3390/nu11112664.CrossRef

102.

Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Increased levels of calprotectin in obesity are related to macrophage content: Impact on inflammation and effect of weight loss. Mol Med. 2011;17:1157–67. https://doi.org/10.2119/molmed.2011.00144.CrossRefPubMedPubMedCentral

103.

Sabater M, Moreno-Navarrete JM, Ortega FJ, et al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab. 2010;95:4720–8. https://doi.org/10.1210/jc.2010-0630.CrossRefPubMed

104.

Rodríguez A, Gómez-Ambrosi J, Catalán V, et al. The ghrelin O-Acyltransferase-Ghrelin system reduces TNF-α-Induced apoptosis and autophagy in human visceral adipocytes. Diabetologia. 2012;55:3038–50. https://doi.org/10.1007/s00125-012-2671-5.CrossRefPubMed

105.

Obesity FG. Aquaporin enters the picture. Nature. 2005;438:436–7. https://doi.org/10.1038/438436b.CrossRef

106.

Méndez-Giménez L, Rodríguez A, Balaguer I, Frühbeck G. Role of aquaglyceroporins and caveolins in energy and metabolic homeostasis. Mol Cell Endocrinol. 2014;397:78–92. https://doi.org/10.1016/j.mce.2014.06.017.CrossRefPubMed

107.

Lombardi R, Airaghi L, Targher G, et al. Liver fibrosis by FibroScan independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver Int. 2020:347–54. https://doi.org/10.1111/liv.14274.

108.

Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005:1313–21. https://doi.org/10.1002/hep.20701.

109.

Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25. https://doi.org/10.1002/hep.21178.CrossRefPubMed

110.

Targher G, Byrne CD, Lonardo A, et al. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis of observational studies. J Hepatol. 2016;65(3):589–600. https://doi.org/10.1016/j.jhep.2016.05.013.CrossRefPubMed

111.

Perdomo CM, Ezponda A, Córdoba JMN, Herrero JI, Bastarrika G, Frühbeck G, et al. Transient elastography and serum markers of liver fibrosis associate with epicardial adipose tissue and coronary artery calcium in NAFLD. Sci Rep. 2022:1–10. https://doi.org/10.1038/s41598-022-10487-3.

112.

Xie Q, Zhou X, Huang P, et al. The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: A meta-analysis. PLoS One. 2014;9(4):e92772. https://doi.org/10.1371/journal.pone.0092772.CrossRefPubMedPubMedCentral

113.

Lassen PB, Charlotte F, Liu Y, et al. The fat score, a fibrosis score of adipose tissue: Predicting weight-loss outcome after gastric bypass. J Clin Endocrinol Metab. 2017;102:2443–53. https://doi.org/10.1210/jc.2017-00138.CrossRef

114.

Goldstein N, Kezerle Y, Gepner Y, et al. Higher mast cell accumulation in human adipose tissues defines clinically favorable obesity sub-phenotypes. Cells. 2020;9(6):1508. https://doi.org/10.3390/cells9061508.CrossRefPubMedPubMedCentral

115.

Cotillard A, Poitou C, Torcivia A, et al. Adipocyte size threshold matters: Link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab. 2014;99:1466–70. https://doi.org/10.1210/jc.2014-1074.CrossRef

116.

Frühbeck G, Gómez-Ambrosi J, Salvador J. Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J. 2001;15:333–40. https://doi.org/10.1096/fj.00-0249com.CrossRefPubMed

117.

Frühbeck G, Gómez-Ambrosi J. Modulation of the leptin-induced white adipose tissue lipolysis by nitric oxide. Cell Signal. 2001;13:827–33. https://doi.org/10.1016/S0898-6568(01)00211-X.CrossRefPubMed

118.

Pulido MR, Diaz-Ruiz A, Jiménez-Gómez Y, et al. Rab18 dynamics in adipocytes in relation to lipogenesis, lipolysis and obesity. PLoS One. 2011;6. https://doi.org/10.1371/journal.pone.0022931.

119.

Poulain-Godefroy O, Lecoeur C, Pattou F, et al. Inflammation is associated with a decrease of lipogenic factors in omental fat in women. Am J Physiol. 2008;295:1–7. https://doi.org/10.1152/ajpregu.00926.2007.CrossRef

120.

Stefan N, Häring HU, Hu FB, Schulze MB. Metabolically healthy obesity: Epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152–62. https://doi.org/10.1016/S2213-8587(13)70062-7.CrossRefPubMed

121.

Zhou Z, Macpherson J, Gray SR, Gill JMR, Welsh P, Celis-Morales C, et al. Are people with metabolically healthy obesity really healthy? A prospective cohort study of 381,363 UK Biobank participants. Diabetologia. 2021;64:1963–72. https://doi.org/10.1007/s00125-021-05484-6.CrossRefPubMedPubMedCentral

122.

Perdomo CM, Núñez-Córdoba JM, Ezponda A, et al. Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease. Front Med (Lausanne). 2022;20(9):1023583. https://doi.org/10.3389/fmed.2022.1023583.CrossRef

123.

Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014;37:2813–21. https://doi.org/10.2337/dc14-0937.CrossRefPubMed

124.

Chang Y, Ryu S, Suh BS, et al. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes. 2012;36:1187–94. https://doi.org/10.1038/ijo.2011.247.CrossRef

125.

Lönn M, Mehlig K, Bengtsson C, Lissner L. Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J. 2010;24:326–31. https://doi.org/10.1096/fj.09-133058.CrossRefPubMed

126.

Weyer C, Foley JE, Borgadus C, et al. Enlarged subcutaneous adbominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. Diabetologia. 2000;43:1498–506. https://doi.org/10.1007/s001250051560. PMID: 11151758.CrossRefPubMed

127.

Elías-López D, Vargas-Vázquez A, Mehta R, et al. Natural course of metabolically healthy phenotype and risk of developing Cardiometabolic diseases: a three years follow-up study. BMC Endocr Disord. 2021;21:1–12. https://doi.org/10.1186/s12902-021-00754-1.CrossRef

128.

Hosseinpanah F, Tasdighi E, Barzin M, et al. The association between transition from metabolically healthy obesity to metabolic syndrome, and incidence of cardiovascular disease: Tehran lipid and glucose study. PLoS One. 2020;15:1–13. https://doi.org/10.1371/journal.pone.0239164.CrossRef

129.

Giardina S, Hernández-Alonso P, Salas-Salvadó J, et al. Modulation of human subcutaneous adipose tissue MicroRNA profile associated with changes in adiposity-related parameters. Mol Nutr Food Res. 2018;62:1–24. https://doi.org/10.1002/mnfr.201700594.CrossRef

130.

Ortega FJ, Mercader JM, Catalán V, et al. Targeting the circulating microRNA signature of obesity. Clin Chem. 2013;59:781–92. https://doi.org/10.1373/clinchem.2012.195776.CrossRefPubMed

131.

Liao CH, Wang CY, Liu KH, et al. MiR-122 marks the differences between subcutaneous and visceral adipose tissues and associates with the outcome of bariatric surgery. Obes Res Clin Pract. 2018;12:570–7. https://doi.org/10.1016/j.orcp.2018.06.005.CrossRefPubMed

132.

van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss — the role of adipose tissue. Nat Rev Endocrinol. 2019;15:274–87. https://doi.org/10.1038/s41574-018-0148-4.CrossRefPubMed

133.

Perdomo CM, Cohen RV, Sumithran P, Clément K, Frühbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401:1116–30.CrossRefPubMed

134.

Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32:1005–15. https://doi.org/10.1007/s11695-021-05884-y.CrossRefPubMed

135.

Badurdeen D, Hoff AC, Hedjoudje A, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021;93:1316-1324.e1. https://doi.org/10.1016/j.gie.2020.10.016.CrossRefPubMed

136.

Brunaldi VO, Jirapinyo P, de Moura DTH, et al. Endoscopic treatment of weight regain following roux-en-Y gastric bypass: a systematic review and meta-analysis. Obes Surg. 2018;28:266–76. https://doi.org/10.1007/s11695-017-2986-x.CrossRefPubMed

137.

Semlitsch T, Stigler FL, Jeitler K, et al. Management of overweight and obesity in primary care—A systematic overview of international evidence-based guidelines. Obes Rev. 2019;20:1218–30. https://doi.org/10.1111/obr.12889.CrossRefPubMedPubMedCentral

138.

Acosta A, Camilleri M, Abu Dayyeh B, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: A pragmatic trial in an obesity clinic. Obesity. 2021;29:662–71. https://doi.org/10.1002/oby.23120.CrossRefPubMed

Title: Towards an adiposity-related disease framework for the diagnosis and management of obesities
Authors: Carolina M. Perdomo
Icíar Avilés-Olmos
Dror Dicker
Gema Frühbeck
Publication date: 10-05-2023
Publisher: Springer US
Keywords: Obesity
Obesity
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 5/2023
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-023-09797-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2023

Advancing precision public health for obesity in children

Phenotyping the obesities: reality or utopia?

Relevance of body composition in phenotyping the obesities

How to address weight regain after bariatric surgery in an individualized way

Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes

Obesity phenotypes and cardiovascular risk: From pathophysiology to clinical management

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials